Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Neumann Capital Management LLC

Neumann Capital Management LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 39,490 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Gilead Sciences accounts for 1.5% of Neumann Capital Management LLC’s portfolio, making the stock its 17th largest position. Neumann Capital Management LLC’s holdings in Gilead Sciences were worth $4,425,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Newbridge Financial Services Group Inc. purchased a new position in Gilead Sciences in the 4th quarter valued at about $33,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 216 shares during the period. Morton Brown Family Wealth LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $35,000. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $35,000. Finally, Synergy Investment Management LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $40,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on GILD shares. BMO Capital Markets increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Wells Fargo & Company boosted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,000 shares of company stock valued at $4,630,310. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 0.7%

GILD opened at $109.30 on Thursday. The firm’s 50 day moving average is $105.40 and its 200-day moving average is $101.91. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $135.96 billion, a P/E ratio of 295.41, a P/E/G ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.32) EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.89%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.